Kaleido Biosciences, Inc. Overview
Pro stress-test →Kaleido Biosciences was a clinical-stage biotechnology company focused on developing Microbiome Metabolic Therapies (MMTs) to leverage the microbiome for treating disease. The company pursued a chemistry-driven platform to modulate microbial metabolism and improve human health across inflammatory, immune-mediated, and rare disease indications.
Strategic Profile
Pro stress-test →Kaleido differentiated itself through its novel approach to activating rather than inhibiting microbiome function. Founded by Flagship Pioneering in stealth mode (2015–2017) with an experienced management team and expanded pipeline, the company went public on NASDAQ in 2019 but ultimately ceased operations.
Competitive Landscape
Pro stress-test →Kaleido competed in the broader microbiome therapeutics space against established pharmaceutical and biotechnology companies. Comparable competitors historically included early-stage microbiome companies and larger pharma entities developing infectious disease and immune-modulating therapies. The company ultimately could not sustain competitive positioning in this crowded landscape.
Industry Context
Kaleido Biosciences, Inc. operates in Microbiome therapeutics.
Key facts
Founded: 2015 · Headquarters: Lexington, Massachusetts · Employees: 51–200 (as of last active period) · Revenue: N/A · Market cap: N/A